Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination.

Journal: Clinical pharmacology in drug development

PMID: 27163502

Abstract

PURPOSE: The purpose of this study was to investigate potential systemic pharmacokinetic interactions between intranasal fluticasone furoate (FF) and levocabastine (LEVO) when delivered simultaneously via a metered atomizing spray pump.

Authors

Ann Allen

GSK R&D, Gunnels Wood Road, Stevenage and Ware, Herts, UK.
Robert D Murdoch

GSK R&D, Gunnels Wood Road, Stevenage and Ware, Herts, UK.
Philippe Bareille

GSK R&D, Gunnels Wood Road, Stevenage and Ware, Herts, UK.
Olivia Burns

GSK R&D, Abbotsford, Australia.
Stephen Hughes

GSK R&D, Gunnels Wood Road, Stevenage and Ware, Herts, UK.
Ashutosh Gupta

GSK R&D, Bangalore, India.
Sam R Miller

GSK R&D, Gunnels Wood Road, Stevenage and Ware, Herts, UK.

Keywords

Administration, Intranasal Adult Androstadienes Biological Availability Cross-Over Studies Drug Combinations Female Glucocorticoids Histamine H1 Antagonists, Non-Sedating Humans Male Middle Aged Piperidines Young Adult

External Resources

View on PubMed Access via DOI PubMed (27163502)

Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals